Intravenous immunoglobulin for rheumatic diseases
Record ID 32006000994
English
Authors' objectives:
Intravenous immunoglobulin (IVIG) therapy is used to provide passive immunity or to alter the immune response by increasing an individual's antibody titer and antigen-antibody reaction potential. IVIG has been investigated as a treatment for patients with rheumatic diseases, with the goals of alleviating symptoms and inducing sustained remissions from disease activity through anti-inflammatory and immunomodulatory effects.
Authors' methods:
Review
Details
Project Status:
Completed
Year Published:
2006
URL for published report:
http://www.hayesinc.com/hayes/crd/?crd=1988
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Immunoglobulins, Intravenous
- Rheumatic Diseases
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
<p>HAYES, Inc.</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.